abeona
therapeutics
announces
appointment
michael
amoroso
chief
operating
officer
new
york
cleveland
globe
newswire
abeona
therapeutics
nasdaq
abeo
leader
gene
cell
therapy
today
announced
michael
amoroso
senior
vice
president
chief
commercial
officer
abeona
promoted
chief
operating
officer
serve
company
principal
executive
operating
officer
effective
november
newly
created
role
abeona
amoroso
responsibilities
broaden
include
oversight
leadership
operations
including
limited
research
clinical
development
regulatory
medical
commercial
corporate
affairs
business
development
michael
years
strategic
operational
leadership
experience
biotechnology
pharmaceutical
industries
including
working
within
commercialization
teams
across
clinical
development
regulatory
affairs
medical
affairs
major
global
markets
said
steven
rouhandeh
chairman
abeona
board
directors
recent
highly
relevant
experience
commercial
development
novel
therapies
underserved
patient
populations
serve
abeona
well
company
seeks
advance
clinical
programs
toward
providing
novel
gene
cell
therapies
patients
currently
approved
treatment
amoroso
stated
abeona
significant
foundation
place
compelling
vision
great
people
deep
science
robust
pipeline
advanced
early
stage
programs
experienced
talented
team
abeona
remains
committed
serving
patients
recessive
dystrophic
epidermolysis
bullosa
rdeb
sanfilippo
syndrome
focused
completing
enrollment
pivotal
phase
study
rdeb
phase
studies
sanfilippo
syndrome
type
mps
iiia
sanfilippo
syndrome
type
b
mps
iiib
amoroso
served
senior
vice
president
chief
commercial
officer
abeona
since
july
prior
joining
abeona
amoroso
held
various
senior
level
commercial
positions
leading
biopharmaceutical
companies
including
kite
eisai
celgene
corporation
subsidiary
squibb
company
sanofi
kite
responsible
company
worldwide
commercial
organization
leading
commercialization
efforts
autologous
car
therapy
future
cell
therapy
pipeline
kite
amoroso
senior
vice
president
americas
eisai
commercial
oncology
business
group
accountable
teams
charged
creating
driving
commercial
strategy
implementation
company
approved
products
assets
previously
amoroso
worked
celgene
six
years
several
commercial
roles
serving
organization
commercial
lead
car
therapy
programs
capacity
helped
celgene
develop
organizational
model
commercialize
cell
therapies
including
specialized
manufacturing
customer
services
patients
lymphoma
myeloma
joining
celgene
amoroso
held
various
marketing
sales
leadership
positions
year
tenure
sanofi
amoroso
earned
management
stern
school
business
new
york
university
biological
sciences
summa
cum
laude
rider
university
abeona
therapeutics
abeona
therapeutics
biopharmaceutical
company
developing
gene
cell
therapies
serious
diseases
abeona
clinical
programs
include
autologous
cell
therapy
recessive
dystrophic
epidermolysis
bullosa
phase
development
well
novel
gene
therapies
sanfilippo
syndrome
types
b
mps
iiia
mps
iiib
respectively
phase
development
company
portfolio
gene
therapies
also
features
disease
abeona
novel
capsids
shown
potential
improve
tropism
profiles
variety
devastating
diseases
abeona
fully
functional
gene
cell
therapy
gmp
manufacturing
facility
produces
pivotal
phase
study
capable
clinical
commercial
production
gene
therapies
information
visit
statements
press
release
contains
certain
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
involve
risks
uncertainties
statements
include
statements
company
exploring
strategic
options
including
sale
assets
sale
company
attempted
identify
statements
terminology
may
believe
estimate
expect
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
constitute
intended
identify
statements
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
numerous
risks
uncertainties
including
limited
potential
impacts
pandemic
business
operations
financial
condition
outcome
strategic
review
continued
interest
rare
disease
portfolio
ability
enroll
patients
clinical
trials
outcome
future
meetings
food
drug
administration
regulatory
agencies
impact
competition
ability
secure
licenses
technology
may
necessary
commercialize
products
ability
achieve
obtain
necessary
regulatory
approvals
impact
changes
financial
markets
global
economic
conditions
risks
associated
data
analysis
reporting
risks
disclosed
company
recent
annual
report
form
subsequent
quarterly
reports
form
periodic
reports
filed
securities
exchange
commission
company
undertakes
obligation
revise
statements
update
reflect
events
circumstances
occurring
date
press
release
whether
result
new
information
future
developments
otherwise
except
required
federal
securities
laws
investor
media
contact
greg
gin
vp
investor
relations
abeona
therapeutics
